The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

With the aim to add a “revenue generating CDMO arm,” Lantheus Holdings has bought New Jersey-based radiopharmaceutical ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront.

Lantheus ( ($LNTH) ) has shared an update. On January 27, 2025, Lantheus Medical Imaging, a subsidiary of Lantheus Holdings, announced an ...

The acquisition provides Lantheus access to Evergreen’s radioligand therapy (RLT) manufacturing infrastructure. Credit: Love Employee via Getty Images. US-based radiopharmaceutical company Lantheus ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment ...